Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...

Investing.com -- Jefferies initiated coverage of Biogen with a Buy rating, saying the U.S. biotech has multiple catalysts in 2026 that could help lift the stock, including stronger sales of ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the ...